24-hour IOP-lowering Effect of 0.01% Bimatoprost

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the 24-hour IOP-lowering efficacy of 0.01% bimatoprost once daily in patients with glaucoma or ocular hypertension

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• primary open-angle glaucoma or ocular hypertension

Exclusion Criteria:

• Women of childbearing potential previous glaucoma surgery presence of other eye disease